Meldungen zum Thema Health

ForaCare Suisse AG

FORA® Diamond GD50 Blood Glucose Monitoring Device Used in United4Health European Project via Diabtel.net / Project Aims to Demonstrate Value of Remote Monitoring for Management of Chronic Diseases

St. Gallen (ots) - ForaCare Suisse AG located in St. Gallen, Switzerland, announced today its Diamond GD50 health monitoring device is featured in the "United4Health European Project" via its partnership with Meter Ltd., FORA's Italian distributor. The United4Health European Project aims to demonstrate the value of ...

Isofol Medical AB

Isofol Medical Share Issue Oversubscribed, Securing Over SEK 39 Million to Strengthen the Ongoing Phase II Clinical Development Program of Modufolin®

Gothenburg, Sweden (ots/PRNewswire) - Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology, will use the investment to support the clinical program with Modufolin®, Isofol's lead drug candidate. Modufolin® is a novel folate-based compound being ...

UC RUSAL

Trials of a New Vaccine for Ebola to Take Place at RUSAL's Medical Centre in Guinea

Moscow (ots/PRNewswire) - UC RUSAL (SEHK: 486; Euronext: RUSAL/RUAL; Moscow Exchange: RUAL/RUALR), a leading global aluminium producer, co-organized a roundtable discussion "Ebola vaccine from Russia: the first lessons and outlook into the future". The Minister of Health, Veronika Skvortsova and the Head of the Russian Federal Service for Surveillance on Consumer ...

GfK SE

European Optics Market Over EUR17 Billion in 2015

Milan (ots/PRNewswire) - GfK has announced its latest figures for key European optics markets (Italy, France, Spain and Germany), confirming a turnover of over EUR17 billion for total year 2015. GfK's Optics Panel tracks sales data for sunglasses, frames, spectacle lenses, contact lenses and care products for contact lenses. The 2015 figures show a 7.0 percent growth in sales value for the optical market across Italy, ...

Oxitec Ltd

FDA Publishes Preliminary Finding of No Significant Impact on Oxitec's Self-limiting Mosquito

Oxford, England (ots/PRNewswire) - The US Food and Drug Administration's Center for Veterinary Medicine (FDA-CVM) today released in the Federal Register a preliminary finding of no significant impact (FONSI) on Oxitec's self-limiting OX513A Aedes aegypti mosquito for an investigational trial in the Florida Keys. The finding agrees with the draft environmental ...

LipiDiDiet Consortium

Two-year, EU-funded Study Reveals a Medical Food in the Form of a Daily Nutritional Drink Can Help to Conserve Memory, the Ability to Think and Perform Everyday Tasks, as well as Reduce Brain Shrinkage in People with Very Early Alzheimer's Disease (AD...

Athens, Greece (ots/PRNewswire) - Topline-results of the first randomised clinical trial in the world to investigate the effects of a nutritional intervention in very early AD (pre-dementia) [1] Topline results from the European LipiDiDiet clinical trial were presented today as part of a late-breaking presentation ...

HRA Pharma Deutschland GmbH

A Frisky Continent: European Women's Attitudes to Sex and Emergency Contraception Revealed!

London (ots/PRNewswire) - Direct access to the morning after pill in pharmacy has made making asmart, positive decision easier, for women not ready to have a baby New research, released on International Women's Day, shows that across Europe, more than three in four women (77%) are aware of the morning after pill as an option for managing the risk of an unplanned ...

Medtronic

Medtronic Avila(TM) Interbody Fusion Device Launched in Europe

Tolochenaz, Switzerland (ots/PRNewswire) - European innovation delivers titanium family of cages to support twin surgical objectives of bone fusion and sagittal realignment for improved patients' outcomes. Medtronic PLC (NYSE: MDT), the global leader in medical technology, today announced the launch of AVILA(TM), its new family of interbody fusion devices for L2-S1 levels in open and minimally invasive ALIF and OLIF ...

LEO Pharma

New Preclinical Data for Calcipotriol/betamethasone dipropionate (0,005%/0,05%) Foam Presented at American Academy of Dermatology Congress

Ballerup, Denmark (ots/PRNewswire) - Data presented in a Late Breaking Science session at the 74th Annual Meeting of the American Academy of Dermatology (AAD) in Washington, D.C. demonstrate that calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) foam formulation is a stable supersaturated solution ...

Astellas Pharma EMEA

Astellas Pharma Europe Ltd. Announces New President of EMEA Operations

Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma Inc. (TSE:4503), is pleased to announce that Mr Yukio Matsui has been appointed as President of EMEA Operations, with responsibility for the company's commercial operations in Europe, the Middle East and Africa. Yukio will assume his new position on 1st April 2016. Since ...

Debiopharm International SA

Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat® Against Nippon Kayaku Co., Ltd.

Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Debiopharm an overall victory for the first instance demanding the suspension of patent infringement of ...

Shire Pharmaceuticals Group Plc

Developments to Income Access Share Arrangements - Elections for the Interim Dividend in Respect of the Six Months to December 31, 2015

Dublin (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") reminds shareholders of important developments relating to the Company's Income Access Share arrangements ("IAS Arrangements"). All shareholders who wish to receive, or continue to receive, UK sourced dividends via the IAS Arrangements (and ...

Hitachi Medical Systems Europe Holding AG

2

Hitachi Aloka will present the ARIETTA V70*1 with enhanced Elastography functions

Hitachi Medical Systems Europe Holding AG

2

Hitachi Aloka launches two new, highly flexible Diagnostic Ultrasound Systems, ARIETTA Precision and ARIETTA Prologue

Novo Nordisk

Xultophy® (insulin degludec/liraglutide; IDegLira) is cost-effective versus current basal insulin intensification in people with uncontrolled type 2 diabetes in the UK

Glasgow, Scotland (ots/PRNewswire) - This material is intended for European and UK medical media only. For journalistic assessment and preparation before publication. New findings show that Xultophy® (insulin degludec/liraglutide; IDegLira), the first once-daily combination of a long-acting basal insulin ...

Accuray Europe

Accuray and GE Capital Healthcare Equipment Finance Announce Healthcare Financing Collaboration Agreement

Paris and London (ots/PRNewswire) - New Agreement Provides Healthcare Professionals with Streamlined, Cost-Effective Options for Accessing the CyberKnife® and TomoTherapy® Systems Accuray Europe and GE Capital Healthcare Equipment Finance announced today they have signed a collaboration agreement to develop ...

ViiV Healthcare

ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir

London (ots/PRNewswire) - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the 41 week phase IIa ECLAIR study, which evaluated the safety, tolerability, dosing and satisfaction with the ...

Astellas Pharma Europe Limited

Britain Facing Social Care 'Time-bomb' with Thousands of People Underprepared to Look After Themselves in Old Age

Chertsey, England (ots/PRNewswire) - Experts say the knock-on effect of lack of planning for later life, as highlighted in poll conducted for this year's ASTELLAS INNOVATION DEBATE[TM],will further impact upon stretched NHS resources Results from a new survey for the annual Astellas Innovation Debate have ...

ViiV Healthcare

ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment

London (ots/PRNewswire) - 32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented ...

Janssen Sciences Ireland UC

First Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE 2 Study Results Presented at CROI

Cork, Ireland (ots/PRNewswire) - Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity to daily oral 3-drug combination Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, (Janssen) announced 32-week data from an ongoing phase IIb study. A ...

GlaxoSmithKline Plc (GSK)

GSK's Global HIV Business ViiV Healthcare Completes Transactions to Acquire Bristol-Myers Squibb's R&D HIV Assets

London (ots/PRNewswire) - GlaxoSmithKline plc (LSE: GSK) today announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has completed two previously announced transactions with Bristol-Myers Squibb to acquire its late-stage HIV ...

Sanofi Pasteur MSD GmbH

Sanofi Pasteur MSD Welcomes European Initiatives to set Vaccination as Standard of Prevention in Seniors

Lyon, France (ots/PRNewswire) - Results of review-based evidence on the public healthvalue of vaccination for seniors in Europe presented at WAidid congress The first Biennial Congress of the World Association for Infectious Diseases and Immunological Disorders (WAidid), has been held in Milan on February 18-20, ...

Sanofi Pasteur MSD GmbH

Vaxelis®, New Fully-liquid Paediatric Hexavalent Vaccine Approved in the European Union

Lyon, France (ots/PRNewswire) - This decision opens the way to making Vaxelis® available to infants and toddlers in European countries Sanofi Pasteur MSD announced today that the European Commission has granted the marketing authorization for Vaxelis®, a new fully-liquid hexavalent vaccine indicated for primary and booster vaccination of infants and toddlers from the ...

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Launches Once-Daily LIXIANA? Sales Alliance in Europe

Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its European subsidiary, Daiichi Sankyo Europe GmbH Group (headquartered in Munich, Germany; hereafter, DSE), has granted exclusive rights to Merck & Co, Inc., Kenilworth, NJ, USA (NYSE: MRK), known as MSD outside the US and Canada (hereafter, MSD) to market the oral, once-daily anti-coagulant, LIXIANA® (edoxaban), ...